Objective: To investigate the efficacy of escitalopram in treatment of premature ejaculation (PE).

Design: A randomized, double-blind placebo-controlled study.

Methods: Patients with PE (n=30) were randomly divided into two treatment groups: a group receiving Escitalopram I 0 mg daily for I  month (n=l 5); and a group receiving placebo for 1 month (n= 15). A modified version of the Chinese Index of Sexual Punction for PE was used for patient evaluation at initial visit, at 10 days intervals after start of treatment for I  month, and at 2 months after stopping treatment.

Results: The mean score ofintra-vaginalejaculation latency time (IBLl) was significantly higher in escitalo pram group as compared to placebo group after 30 days of treatment (5.6±0.7  vs 6.8±0.4,  P < 0.03). At 90 days (2 month after stopping treatment), IELT score in the escitalopram group was significantly higher than the placebo group (6.7 ±0.8 vs 3.4±0.5, P=0.01).

Conclusion: Escitalopram is an effective therapeutic option for patient with PE that may help provide long term control over ejaculation.